厄贝沙坦氢氯噻嗪对原发性高血压患者血脂水平与颈动脉内膜中层厚度的影响

The effect of lipid levels and carotid Intima-media thickness by irbesartan hydrochlorothiazide on patients with essential hypertension

目的分析厄贝沙坦氢氯噻嗪对原发性高血压患者血脂水平与颈动脉内膜中层厚度的影响。方法选取我院2014年10月至2015年10月收治的80例高血压患者,参照抽签法分成观察组与对照组,各40例,观察组采取厄贝沙坦氢氯噻嗪治疗,对照组采取硝苯地平治疗,比较两组患者治疗前后血脂水平、血压、IMT及炎性因子变化,不良反应率。结果治疗后,观察组血脂TC水平低于对照组[4.53±0.32 vs 4.67±0.30]mmol/L,TG水平低于对照组[1.71±0.02 vs 1.86±0.01]mmol/L,LDL-C水平低于对照组[3.12±0.41 vs 3.30±0.36]mmol/L,HDL-C水平高于对照组[2.11±0.21 vs 2.00±0.15]mmol/L,比较差异明显(P<0.05);舒张压低于对照组[86.52±2.11 vs 90.63±2.25]mm Hg,收缩压低于对照组[108.74±5.65 vs 118.53±6.70]mm Hg,IMT低于对照组[0.85±0.13 vs 0.93±0.10]mm,比较有统计学意义(P<0.05);炎性因子CRP水平低于对照组[1.62±0.24 vs 1.75±0.21]mg/L,MCP-1水平低于对照组[92.35±4.08 vs 96.37±4.25]μg/L,IL-6水平低于对照组[16.82±1.40 vs 18.96±1.43]μg/L,比较差异显著(P<0.05),观察组不良反应率2.50%低于对照组16.88%(P<0.05)。结论原发性高血压运用厄贝沙坦氢氯噻嗪治疗安全性高,可有效控制血压,降低血脂水平及颈动脉内膜中层厚度,减轻动脉粥样硬化,促进患者恢复。

Objective ： To study the effect of lipid levels and carotid intima-media thickness by irbesartan hydrochlorothiazide on patients with essential hypertension. Methods： Eighty eases of essential hypertension from October 2014 to October 2015 were admitted, divided into the observation group and the control group of 40 patients each by drawing lots, Observation group were treated by irbesartan hydroehlorothiazide therapy, and the control group by nifedipine, two groups were compared before and after treatment in lipid levels, blood pressure, IMT and inflammatory factors change and the rate of adverse reactions. Results ： After treatment, the observation group were lower than the control group in blood lipid levels TC [ 4.53 ±0.32 vs 4.67 ± 0.30 ] mmol/L, TG levels than the control group [ 1.71 ±0.02 vs 1.86 ± 0.01 ] mmol/L, LDL-C level lower than the control group [3.12 ±0.41 vs 3.30 ±0.36] mmol/L, HDL-C level higher than [2.11 ±0.21 vs 2.00 ±0.15] mmol/L, the difference was significant （ P 〈 0.05 ） ; diastolic blood pressure was lower than that in the control group [ 86.52 ± 2.11 vs 90.63 ±2.25 ] mmHg, systolic blood pressure lower than that of the control group [ 108.74 ± 5.65 vs 118.53 ± 6. 70 ] ramHg, IMT was lower than that of the control group [ 0.85 ± 0.13 vs 0.93 ±0.10 ] ram, which was statistically significant （P 〈 0.05 ） ; inflammatory factor CRP levels were lower than those in the control group [ 1.62 ±0.24 vs 1.75 ± 0.21 ] rag/L, MCP- 1 levels than the control group [ 92.35 ± 4.08 vs 96.37 ± 4.25 ]μg/L, IL 6 levels lower than the control group [ 16. 82 ± 1.40 vs 18.96 ± 1.43 ] μg,/L, the difference was significant （ P 〈 0.05 ）. The rate of adverse reactions observed 2.50% was lower than that of the control group, 16.88% （ P 〈 0.05 ）. Conclusion： The use of essential hypertension Irbesartan Hydroehlorothiazide is safe in treatment, can effectively control blood pressure, reduce blood lipid levels and carotid artery intima-media thickness and atheroselerosis, and improve patient recovery.